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Abstract
Background: Vascular endothelial growth factor (VEGF) is a primary stimulant of angiogenesis under physiological
and pathological conditions. Anti-VEGF therapy is a clinically proven strategy for the treatment of a variety of
cancers including colon, breast, lung, and renal cell carcinoma. Since VEGFR2 is the dominant angiogenic signaling
receptor, it has become an important target in the development of novel anti-angiogenic therapies. We have
reported previously the development of an antagonistic VEGFR2 peptoid (GU40C4) that has promising anti-
angiogenic activity in vitro and in vivo.
Methods: In the current study, we utilize a derivative of GU40C4, termed GU81 in therapy studies. GU81 was
tested alone or in combination with doxorubicin for in vivo efficacy in the MMTV-PyMT transgenic model of breast
cancer.
Results: The derivative GU81 has increased in vitro efficacy compared to GU40C4. Single agent therapy
(doxorubicin or GU81 alone) had no effect on tumor weight, histology, tumor fat content, or tumor growth index.
However, GU81 is able to significantly to reduce total vascular area as a single agent. GU81 used in combination
with doxorubicin significantly reduced tumor weight and growth index compared to all other treatment groups.
Furthermore, treatment with combination therapy significantly arrested tumor progression at the premalignant
stage, resulting in increased tumor fat content. Interestingly, treatment with GU81 alone increased tumor-VEGF
levels and macrophage infiltration, an effect that was abrogated when used in combination with doxorubicin.
Conclusion: This study demonstrates the VEGFR2 antagonist peptoid, GU81, enhances the anti-tumor activity of
doxorubicin in spontaneous murine MMTV-PyMT breast tumors.
Background
Breast cancer is the most frequently diagnosed malig-
nancy in women in North America. Advancements in
standard treatment regimens have improved the overall
outlook for breast cancer patients in recent years, how-
ever, 40,000 women a year succumb to this disease,
highlighting the need for better treatment modalities [1].
Angiogenesis, the development of new blood vessels
from existing vessels, is required for tumor progression
and metastasis [2]. For this reason, tumor angiogenesis
has become an important target for cancer therapy [3,4].
Vascular endothelial growth factor (VEGF), a primary
angiogenic growth factor in many tumor types, binds to
and activates VEGFR1 and VEGFR2 [5]. VEGFR2 is the
dominant angiogenic signaling receptor, while the func-
tion of VEGFR1 is less defined. As the angiogenic VEGF
receptor, VEGFR2 has become a central target in devel-
oping anti-angiogenic therapies.
Bevacizumab (Avastin®, Genetech), which binds to
VEGF and prevents VEGF from binding to both
VEGFR1 and VEGFR2, was the first clinically approved
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anti-angiogenic therapy [6]. Bevacizumab was recently
approved for the treatment of HER2/NEU-negative
breast cancer in combination with chemotherapy, vali-
dating the use of anti-angiogenic therapy in this disease
[7]. The clinical success of bevacizumab has amplified
the number of anti-VEGF therapies being developed and
tested. These therapies may specifically block VEGF,
VEGFR1, or VEGFR2, or promiscuously block both
VEGFRs as well as other receptor tyrosine kinases
[8-11].
We have previously reported the development of a
peptoid, GU40C4, that has promising anti-angiogenic
activity both in vitro and in vivo [12]. GU40C4 signifi-
cantly reduced VEGF-induced VEGFR2 phosphorylation
in both PAE-KDR and HUVEC cells. Furthermore,
GU40C4 significantly reduces VEGF-induced HUVEC
proliferation [12]. GU81, a derivative of GU40C4, was
developed to increase binding affinity and therefore in
vitro and in vivo efficacy. Peptoids are closely related to
peptides, however, peptoids (oligo-N-substituted gly-
cines) are engineered for improved serum stability and
cell permeability compared to peptides [13]. Peptoids
differ from peptides by having the side chain (‘R’ group)
placed on the amide nitrogen of the backbone.
In this study, we assess the in vivo efficacy of GU81, a
derivative of GU40C4, in the MMTV-PyMT transgenic
breast cancer model. The MMTV-PyMT model was
chosen because tumor progression has been extensively
analyzed in this model and closely mirrors the progres-
sion of human disease [14]. Based on our previous work
with GU40C4 [12], we hypothesized that GU81 would
control breast tumor growth both as a single agent and
in combination with chemotherapy. However, our find-
ings indicate that GU81 is not effective as a single agent
in the MMTV-PyMT model of breast cancer, but com-
bination with doxorubicin produces additive effects.
Methods
Production of GU81
GU81 was developed based on the identified ‘minimum
pharamacophore’ [15] of GU40C4 and the complete
development strategy will soon be published elsewhere.
GU40C4, GU81 competition ELISA
96-well ELISA plates were coated with 1 ug/ml mouse
VEGFR1/Fc and VEGFR2/Fc (R&D Systems, Minneapo-
lis, MN) in sensitizing buffer (0.621 g NaHCO3 and 0.275
g Na2CO3 dissolved in 100 mL of ddH2O, pH 9.5) over-
night at 4°C. Each well was washed with 3 × 200 μL phos-
phate-buffered saline (PBS) and blocked with 20%
Aquablock (East Coast Biologics, North Berwick, ME). 50
μL of biotin-labeled GU40C4 (final concentration 75 nM)
was added to each well in the presence or absence 50 μL
unlabeled GU81 (final concentration 7.5 μM) for 2 hours
at room temperature. Each well was washed with 3 × 200
μL in PBS. 50 μL HRP-conjugated strepavidin (Jackson
Immunoresearch, West Grove, PA) was added at a
1:10,000 dilution in PBS for 1 hour at room temperature.
The plate was then developed with HRP substrate and
absorbance was measured at 450 nm.
Fluorescence-based ELISA
White, clear-bottom 96-well plates (Corning Inc., Corn-
ing, NY) were coated with 1 μg/mL recombinant human
VEGFR protein (R&D Systems) in sensitizing buffer
(0.621 g NaHCO3 and 0.275 g Na2CO3 dissolved in 100
mL of ddH2O, pH 9.5) overnight at 4°C. Each well was
washed with 3 × 200 μL of phosphate-buffered saline
(PBS) and blocked with block buffer (Pierce, Rockford,
IL). 50 μL GU81 (about 5 μM) was titrated in at a 4-
fold dilution series. Wells were washed with 5 × 200 μL
of PBS and fluorescence was measured at 520 nm using
a plate reader (Fluostar Optima, BMG Laboratories,
Durham, NC).
VEGFR2 autophosphorylation assay
Experiments were conducted using PAE-KDR (Sibtech
Inc., Brookfield, CT) and HUVEC (Sciencecell, Carlsbad,
CA) cells. Cells were serum starved overnight and trea-
ted with increasing concentrations of GU81 for 15 min
followed by 1.3 nM VEGF for 7 min (Invitrogen, Carls-
bad, CA) or bevacizumab (Avastin™, Genentech, South
San Francisco, CA) treated VEGF at 37°C. Cells were
harvested with lysis buffer, and lysates were separated
by SDS-PAGE and transferred to PVDF membranes.
Membranes were probed with anti phospho-VEGF
receptor 2 (Tyr1175, 19A10) or total anti-VEGFR2 pri-
mary antibodies (Cell Signaling Technology, Danvers,
MA) and subsequently developed with appropriate
HRP-conjugated secondary antibody (BioRad Labora-
tories, Hercules, CA) followed by enhanced chemilumi-
nescent detection (Pierce).
Tumor Model and Treatment
MMTV-PyMT/Fvb transgenic mice were obtained from
the Jackson Laboratory (Bar Harbor, ME) and a colony
was bred and maintained in a pathogen-free facility at
UT Southwestern. All animal studies were performed on
a protocol approved by IACUC at the University of
Texas Southwestern Medical Center. Treatment with
GU81 at 260 ug/day delivered via osmotic pump (total
volume, 100 μl over 19 days, Alzet, Cupertino, CA)
placed i.p. and doxorubicin (2 mg/kg once weekly i.v.)
began when mice reached 6 weeks of age and continued
for 19 days prior to animal sacrifice. Caliper measure-
ments were made twice weekly and tumor volume was
calculated using D × d2 × 0.52, where D is the long dia-
meter and d is the perpendicular short diameter.
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Histology and Immunohistochemistry
Control and treated MMTV-PyMT tumors were fixed in
formalin, embedded in paraffin, sectioned, and stained
with hematoxylin and eosin (H&E) by the Molecular
Pathology Core Laboratory. Tissue was snap frozen in
liquid nitrogen, embedded in OCT media, and sec-
tioned. Sections were fixed in acetone, briefly air-dried
and blocked with 20% Aquablock (East Coast Biologics)
for 30-60 minutes. Primary antibodies were used at a
final concentration of 5-10 μg/ml and include: rabbit
anti-perilipin [16], rabbit anti-adiponectin [17], rabbit
anti-phospho-histone-3 (Ser10) (Upstate, Lake Placid,
NY), rabbit anti-cleaved caspase-3 (Asp 175) (Cell Sig-
naling), rat anti-endomucin (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA), chicken anti-VEGF (Abcam,
Cambridge, MA), and goat anti-F4/80 (Santa Cruz Bio-
technology). Primary antibody was incubated on sections
for one hour at room temperature or overnight at 4°C.
Negative controls were performed by omitting the pri-
mary antibody. Following washes, the appropriate fluor-
ophore conjugated secondary antibody was added
(Jackson Immunoresearch). Fluorescent slides were
cover-slipped using Prolong with DAPI (Invitrogen).
Sections were examined on a Nikon E600 microscope
and images captured with Photometrics coolsnap HQ
camera using Elements Software (Nikon).
Met-1 Cell Assays
Met-1 cells were plated in Dulbecco’s Modified Eagle
Media (DMEM) (Invitrogen) supplemented with 10%
FBS and allowed to adhere O/N. Cells were then treated
with serum-free DMEM in the presence or absence of
2.5 μM GU81. Tumor-conditioned media (TCM) was
collected and RNA harvested using TRIzol (Invitrogen)
according to the manufacturer’s directions at 24, 48, and
72 hours post-treatment. The quality of RNA was evalu-
ated using spectrophotometry. The cDNA used for sub-
sequent PCR was made using iScript (Bio-Rad
Laboratories). The expression of VEGF was analyzed by
quantitative real-time PCR using assay on demand from
Applied Biosystems (Mm00437308_m1). GAPDH
(Applied Biosystems, 4352339E-0909032) assay-on-
demand was used as an internal reference gene to nor-
malize input cDNA. Quantitative real-time PCR was
performed in a reaction volume of 20 μL of cDNA and
each reaction was performed in triplicate. We used the
comparative Ct method to compute relative expression
values. TCM was diluted 1:5 prior to analysis for VEGF
concentration using the Quantikine Mouse VEGF
Immunoassay (R&D Systems).
Statistics
Data were analyzed using GraphPad software (Graph-
Pad Prism version 5.0 for windows; GraphPad
Software, San Deigo, CA, http://www.graphpad.com).
Results are expressed as mean ± SEM. Spearman rank
correlations were used to assess the association
between VEGF levels and macrophage infiltration.
Data was analyzed by t-test or ANOVA and results are
considered significant at p < 0.05.
Results
GU81 inhibits VEGF-induced activation of VEGFR2
GU81 (Figure 1A) is a derivative of the VEGFR2 antago-
nist GU40C4 [12]. We first characterized the ability of
GU81 to compete with GU40C4 for binding to both
VEGFR1 and VEGFR2 (Figure 1B). GU81 potently com-
petes with GU40C4 for binding to both VEGFRs, indi-
cating that these peptoids recognize the same epitope.
We next analyzed the GU81 binding kinetics to
VEGFR2 by fluorescence ELISA (Figure 1C). The mea-
sured binding constant for the GU81:VEGFR2 interac-
tion (KD) was 12 nM, a 3-fold improvement over the
original GU40C4 [12].
To validate the functional activity of the GU81, we
conducted a VEGFR2 autophosphorylation assay [12]. In
brief, PAE-KDR cells were grown, stimulated with
VEGF and treated with increasing concentrations of
GU81. VEGFR2 autophosphorylation levels were then
detected by Western blotting (Figure 1D). We found
that GU81 effectively blocks VEGF-induced VEGFR2
phosphorylation of PAE-KDR cells in a dose-dependent
manner in vitro. Furthermore, through quantification of
phospho-VEGFR2 and total VEGFR2 levels, we deter-
mined that the IC50 value for GU81 is ~430 nM. This is
a 2-fold improvement over the parent compound
GU40C4, which exhibits an IC50 value of approximately
1 μM [12]. For this reason, it is expected that GU81 is a
more potent inhibitor of endothelial cell proliferation
when compared to GU40C4, which inhibits VEGF-
induced endothelial cell proliferation at a concentration
of 1 μM [12].
GU81 controls tumor growth in combination with
doxorubicin
Following the in vitro validation of GU81 as an effective
agent for blocking VEGFR2 autophosphorylation, we
evaluated GU81 efficacy in vivo, as a single agent and in
combination with doxorubicin in the MMTV-PyMT
transgenic breast cancer model. Treatment began when
mice reached 6 weeks of age and continued for 19 days
prior to animal sacrifice. At the time of sacrifice, ani-
mals treated with either doxorubicin alone or GU81 +
doxorubicin had significantly reduced tumor volume
compared to control treated animals (Figure 2A). How-
ever, GU81 in combination with doxorubicin showed a
striking additive effect. Tumor volume was significantly
lower (1.6-fold reduction) in animals treated with GU81
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+ doxorubicin than those treated with doxorubicin alone
(p ≤ 0.01, 2-way ANOVA) (Figure 2A). At time of
necropsy all tumors were excised and weighed. Only
animals treated with GU81 + doxorubicin had signifi-
cantly less tumor burden (total tumor weight) compared
to control treated animals (p ≤ 0.01, 1-way ANOVA)
(Figure 2B). GU81 alone did not have a significant effect
on either tumor volume or tumor weight (Figure 2A, B).
GU81 alters tumor histology and the tumor
microenvironment when used in combination with
doxorubicin
To evaluate the effects of therapy on the tumor micro-
environment, hematoxylin and eosin staining was per-
formed on formalin-fixed, paraffin embedded tumor
sections. Tumors from saline-treated animals were
classified as invasive carcinoma, and treatment with
GU81 alone did not alter this histology (Figure 3).
Tumors from doxorubicin treated animals also dis-
played areas of invasive carcinoma; although the inva-
sive component of the tumor was reduced when
compared to control and GU81-treated animals (Figure
3). In contrast, combination therapy significantly
altered tumor/mammary tissue histology. In these ani-
mals, the mammary lobules were intact and there was
no evidence of invasion. Consequently, more of the
residual adipose tissue remained in the mammary
gland (Figure 3). Thus, whereas control animals and
animals treated with either GUI81 or doxorubicin
alone harbored clearly invasive adenocarcinomas, the
Figure 1 GU81 inhibits VEGF-induced activation of VEGFR2. A) Dimeric structure of the peptoid GU81 B) Biotin-conjugated GU40C4 binds to
both VEGFR1 and VEGFR2 as measured by ELISA. GU81 competes with biotinylated GU40C4 for binding to both receptors. C) Fluorescein-
conjugated GU81 was titrated and analyzed for binding to VEGFR2 as measured by ELISA. KD= 12 nM. D) Serum starved PAE/KDR cells were
stimulated for 7 min with VEGF (1.3 nM) in the presence and absence of the indicated concentration of GU81. Avastin, a blocking anti-VEGF
antibody was used as a positive control for inhibition. Cell lysates were made and separated by SDS-PAGE, transferred to PVDF membranes and
probed for phosphorylated VEGFR2 and total VEGFR2 by Western blotting. E) Quantification and analysis of the results presented in (D). IC50=
430 nM.
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Figure 2 GU81 improves that the anti-tumor efficacy of doxorubicin. MMTV-PyMT mice (age 6 weeks) were treated 19 days with vehicle
alone (control), doxorubicin (dox, 2 mg/kg 1×/week via ip injection in saline), GU81 (260 μg/day via osmotic pump), or GU81 + doxorubicin
(GU81 + dox). A) Tumor volume is displayed as sum of total measurable tumor burden. *, p < 0.05; **, p < 0.01; ***, p < 0.005 vs control, 2-way
ANOVA. B) Total tumor weight was calculated at time of sacrifice (age 60 days). Only GU81 + doxorubicin-treated tumors were significantly
smaller than control treated tumors (p ≤0.01, 1-way ANOVA).
Figure 3 Combination therapy of GU81 and doxorubicin prevents transition from a premalignant to an invasive phenotype. Tumor
tissue was harvested, fixed in formalin, sectioned, and stained with hematoxylin and eosin. Images representative of at least 3 tumors from each
group are shown. Note the dramatic reduction in the number of invasive cells induced by combination therapy. Total magnification 200×; scale
bar, 50 μm.
Lynn et al. BMC Cancer 2010, 10:397
http://www.biomedcentral.com/1471-2407/10/397
Page 5 of 13
lesions in animals treated with combined GU81 and
doxorubicin would be best described as hyperplastic or
premalignant lesions, highlighting the marked additive
effect of these agents (Figure 3).
To quantify the amount of normal breast tissue
remaining in tumors from all treatment groups, immu-
nohistochemistry was performed to evaluate the expres-
sion of the adipocyte markers perilipin and adiponectin
(Figure 4). Perilipin coats lipid droplets in adipocytes
and protects them against the body’s natural lipases
[18]. Adiponectin is secreted exclusively from adipocytes
into the bloodstream where it regulates a number of
metabolic processes including glucose regulation and
fatty acid catabolism [19,20]. There were significantly
higher levels of perilipin in tumors from GU81 + doxor-
ubicin treated animals when compared to tumors from
doxorubicin alone treated mice (p ≤ 0.01, 1-way
ANOVA) (Figure 4B). Similar results were seen when
immunohistochemistry was performed for adiponectin
(Figure 4C) [19,21].
Figure 4 Adipocyte structure is conserved in tumors from mice treated with GU81 and doxorubicin. A) Sections of tumors from each
treatment group were stained by immunofluorescence for perilipin (red), an adipocyte marker, and nuclei (blue). Images representative of each
group are shown. A minimum of 3 tumors from each group were evaluated by immunofluorescence. Total magnification, 200×. B&C) Staining
from a minimum of 5 images from each tumor per treatment group was quantified by evaluating the Cy3 positive area (perilipin(B) adiponectin
(C)). There is significantly more perilipin (B) staining in tumors from mice treated with GU81 + doxorubicin than from tumors treated with either
doxorubicin or GU81 alone (p≤0.05 by Mann-Whitney). Adiponectin (C) staining was significantly increased in tumors from mice treated with
either doxorubicin alone or GU81 and doxorubicin compared to tumors from control-treated animals (p≤0.05, t-test).
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Tumor growth dynamics were further evaluated using
markers for phospho-histone-3, which stains actively
proliferating cells, and cleaved caspase-3, which marks
cells undergoing apoptosis. Tumors from animals trea-
ted with both doxorubicin alone and GU81 + doxorubi-
cin had fewer phospho-histone-3 positive cells when
compared to tumors from control treated animals, indi-
cating that these tumors contained fewer actively prolif-
erating cells (p ≤ 0.01, 1-way ANOVA) (Figure 5B).
GU81 alone had no effect on tumor cell proliferation or
apoptosis (Figure 5B, D). Interestingly, tumors from
doxorubicin treated animals had significantly fewer
active caspase-3 positive cells when compared to tumors
from control-treated animals (p ≤ 0.05, 1-way ANOVA)
(Figure 5D). The number of phospho-histone-3 positive
cells/200× field was divided by the number of cleaved
caspase-3 positive cells/200× field in order to obtain a
growth index. A growth index of 1 indicates that the
same number of cells are proliferating and undergoing
apoptosis per field, whereas a growth index < 1 indicates
that more cells are undergoing apoptosis than are prolif-
erating. Only tumors from GU81 + doxorubicin treated
animals had a significantly lower growth index com-
pared to control treated tumors (p ≤ 0.05, 1-way
ANOVA) (Figure 5E). These results show that whereas
the single agent doxorubicin was cytostatic, combination
therapy was cytocidal, consistent with the observed
in vivo effects on tumor volume and weight.
GU81 decreases total vascular area and vessel size but
not vessel number
To determine if GU81 had any effect on angiogenesis
either alone or in combination with doxorubicin, micro-
vessel density was assessed by immunohistochemical
staining. Surprisingly, GU81 had no effect on total vessel
number either alone or in combination with doxorubicin
(Figure 6A, B). However, GU81 therapy decreased total
vascular area, measured as the percent endomucin posi-
tive area per 200× field, alone (p < 0.001, t-test) and in
combination with doxorubicin (p < .05, t-test) (Figure
6C). Furthermore, vessel size was decreased following all
of the specified treatment regimens (Figure 6D).
GU81 increases VEGF expression and macrophage
infiltration, which is abrogated when used in combination
with doxorubicin
To further evaluate the tumor microenvironment fol-
lowing therapy, we assessed the levels of VEGF and F4/
Figure 5 Combination therapy of doxorubicin and GU81 reduces the growth index of MMTV-PyMT tumors. Tumor sections from each
treatment group were evaluated for phospho-histone-3 (A&B) and active-caspase-3 (C&D) by immunohistochemistry as described in the
methods section. Signal intensity was quantified using Elements software and is displayed and mean +/- SEM. All quantification includes 3
animals/group and 5 sections/animal. D) A growth index was calculated whereby the number of phospho-histone-3 positive cells (actively
proliferating) was divided by the number of active caspase-3 positive cells (undergoing apoptosis). *, p < 0.05; **, p < 0.01 vs control, 1-way
ANOVA and Mann Whitney test.
Lynn et al. BMC Cancer 2010, 10:397
http://www.biomedcentral.com/1471-2407/10/397
Page 7 of 13
80+ macrophage infiltration using immunohistochemis-
try. We found that tumors from GU81-treated animals
had significantly increased levels of VEGF compared to
tumors from control-treated mice (p ≤ 0.05, t-test) (Fig-
ure 7A, B). In contrast, neither treatment with doxoru-
bicin alone or in combination with GU81 had
significant effects on VEGF expression (Figure 6B). To
further investigate the increase in VEGF expression fol-
lowing treatment with GU81, an in vitro system was uti-
lized. Met-1 cells, which are a highly metastatic cell line
derived from a MMTV-PyMT primary tumor [22], were
treated in the presence or absence of 2.5 μM GU81 for
24, 48, and 72 hours. Following treatment, mRNA and
tumor-conditioned media was collected for analysis of
Figure 6 Treatment with GU81 either alone or in combination with doxorubicin reduces total vascular area and vessel size in the
MMTV-PyMT model. Tumor sections from each group were evaluated for various vascular parameters following staining with the endothelial
cell marker endomucin. Representative images from each treatment group are displayed in (A). (B) The number of vessels per 200× field was
evaluated using Nikon Elements software and is displayed as the mean +/- SEM. All quantification includes 3 animals/group and 5 sections/
animal. (C) The total vascular area was calculated using Nikon Elements software and is displayed as the percent fluorescent area per 200× field.
(D) The percent fluorescent area was divided by the total vessel number for each section in order to obtain a relative vessel size. *, p < 0.05;
**, p < 0.01 vs control; ***, p < 0.001, t-test.
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VEGF expression. VEGF mRNA levels are significantly
increased after 72 hours of GU81 treatment (p < 0.05,
1-way ANOVA) (Figure 7C). Furthermore, VEGF pro-
tein levels were significantly increased at all time points
analyzed following treatment with GU81 (p < 0.01, 1-
way ANOVA) (Figure 7D).
Macrophage infiltration into tumors is known to be
influenced by VEGF [9,10,23]; therefore, we examined
macrophage infiltration following therapy using the gen-
eral macrophage marker F4/80. We found that macro-
phage infiltration was significantly increased following
treatment with GU81 (p ≤ 0.05 vs. control-treatment,
t-test) (Figure 8A, B). Furthermore, this effect was
abrogated when GU81 was combined with doxorubicin
(p ≤ 0.05 vs. GU81 alone, t-test) (Figure 6B). Linear
regression analysis reveals a positive correlation between
VEGF levels and macrophage infiltration following the
described treatment regimens (r2 = 0.89) (Figure 8C).
Discussion
In this study, we describe the novel VEGFR2 peptoid
antagonist, GU81. GU81 binds to VEGFR2 with a bind-
ing affinity of 12 nM and displays potent in vitro biolo-
gical efficacy (Figure 1B&1C). We tested the therapeutic
efficacy of GU81, both alone and in combination with
doxorubicin in the extensively characterized sponta-
neous and aggressive MMTV-PyMT model of breast
cancer [14]. While GU81 had little therapeutic efficacy
Figure 7 GU81-alone but not in combination with doxorubicin induces VEGF expression in vivo and in vitro. Tumor sections from each
group were evaluated for VEGF expression (A&B) using immunohisochemistry. The percent VEGF positive area was calculated using Elements
software and is displayed as the mean +/- SEM. All quantification includes 3 animals/group and 5 sections/animal. * p < 0.05 vs control, t-test.
C&D) Met-1 cells were treated with serum free DMEM +/- 2.5 uM GU81 for 24 hr, 48 hr, and 72 hr. mRNA and tumor conditioned media (TCM)
was isolated and analyzed for VEGF levels at each time point. (C) Quantitative real-time PCR analysis reveals a significant increase in VEGF gene
transcription following 72 hrs of GU81 treatment. * p < 0.05 vs SFM, 1-way ANOVA (D) VEGF protein levels were measured in Met-1 TCM using
the Quantikine mouse VEGF ELISA kit (R&D Systems). VEGF secretion was significantly increased at all time points. ** p < 0.01, p < 0.001 vs SFM,
1-way ANOVA.
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when used alone, animals treated with the combination
of GU81 and doxorubicin had decreased tumor burden
(Figure 2A), significantly reduced tumor invasion (Figure
3), increased tumor fat content (Figure 4B), and a lower
tumor growth index (Figure 5E) compared to animals
from all other treatment groups.
We began therapy when mice reached 6 weeks of age,
and at this time most of the mice harbored primary
neoplasia that developed to the hyperplastic stage
[14,24]. In this case, the combination of GU81 + doxor-
ubicin was able to delay tumor progression and prevent
transition from a premalignant to an invasive phenotype.
This striking delay in tumor progression can be attribu-
ted to our use of a “double-edged sword” to target
tumor cells (doxorubicin) and endothelial cells (GU81).
In using this approach we were able to achieve signifi-
cantly better results compared to either agent alone.
Although we do not see a decrease in vessel number fol-
lowing treatment with GU81 either alone or in combi-
nation with doxorubicin, GU81 did induce a decrease in
total vascular area and vessel size (Figure 6). Tumor
blood vessels are dilated, leaky, and inefficient at deliver-
ing both oxygen and chemotherapeutic agents to the
tumor [reviewed in [25]]. Vessel dilation is decreased
following treatment with GU81, which leads us to the
hypothesis that GU81 may be effectively normalizing the
vasculature, decreasing hypoxia, and increasing doxoru-
bicin delivery into the tumor.
Figure 8 GU81-alone but not in combination with doxorubicin induces macrophage infiltration in vivo. Tumor sections from each group
were evaluated for macrophage infiltration by assessment of F4/80+ cells (A&B) using immunohisochemistry. Representative images from saline
and GU81 treated animals are displayed in (A). (B) The percent F4/80 positive area was calculated using Elements software and is displayed as
the mean +/- SEM. All quantification includes 3 animals/group and 5 sections/animal. * p < 0.05 vs control, t-test. (C) Linear regression analysis
reveals a positive correlation between VEGF levels and macrophage infiltration following therapy. r2 = 0.89.
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Interestingly, GU81 does not demonstrate in vivo effi-
cacy as a single agent in the MMTV-PyMT model of
breast cancer [10]. This is consistent with our previous
studies in the MMTV-PyMT model [10] and human
data, which has shown that anti-VEGF therapy provides
little clinical benefit as a single agent in breast cancer
[26]. In contrast, GU40C4, the parent compound,
demonstrated single agent efficacy in the A673 Ewings’
sarcoma xenograft model [12]. GU81, however, does
demonstrate in vivo efficacy as a single agent in the 4T1
syngenic breast cancer model, where it effectively
reduces tumor size and MVD [10]. There are several
possible explanations for the variation in response to
GU40C4 and GU81. Most notable is the difference in
tumor model systems. The MMTV-PyMT model is a
spontaneous model that develops in the mammary fat
pad, which is highly vascularized. While the A673
model is a subcutaneous xenograft model that is highly
dependent upon VEGF activity [27], such that even low
doses of anti-VEGF agents have a striking effect on
tumor growth [28]. The 4T1 model is a syngeneic,
highly metastatic inflammatory breast cancer model.
Interestingly, recent work has identified VEGF as an
autocrine survival factor for these cells under hypoxic
conditions, which may explain the efficacy of GU81 as a
single agent in this model [29]. It is possible that a
higher dose given for a longer period of time would be
more effective at reducing microvessel density in
MMTV-PyMT tumors. Furthermore, it is important to
highlight that treatment with GU81 alone increased
tumor VEGF expression in this model, which may
explain its inability to control tumor burden as a single
agent (Figure 6B). We decided to further investigate this
increase in tumor VEGF expression and confirmed our
in vivo results in an in vitro system (Figure 7C, D).
Tumor cells in primary MMTV-PyMT tumors express
low levels of VEGFR2 (data not shown), however it is
difficult to argue that either VEGF or GU81 may be
having a direct effect on tumor cell proliferation or sur-
vival as we see no change in either proliferation or
apoptosis markers following treatment with GU81 as a
single agent. Met-1 cells also express VEGFR2 and
increased VEGF expression following treatment with
GU81 suggests that there may be an intact negative
VEGF:VEGFR2 feedback loop in these cells. Treatment
with GU81 could inhibit such a negative feedback loop,
resulting in increased VEGF expression.
Macrophage infiltration is associated with poor prog-
nosis in a number of different tumor types, including
breast cancer [30,31]. After establishing that VEGF
levels were increased following treatment with GU81
alone (Figure 6B), we decided to investigate what effect
this increase has on macrophage infiltration, given that
VEGF stimulates macrophage chemotaxis into the
tumor microenvironment. GU81 increases macrophage
infiltration as a single-agent [10], however, this effect is
abrogated when GU81 combined with doxorubicin (Fig-
ure 6D). This increase in macrophage infiltration is puz-
zling as we and others have shown that anti-VEGF
therapy can reduce macrophage infiltration in a number
of pre-clinical models [9,10,23,32,33]. Additionally, we
show that macrophages harvested from a tumor-bearing
animal express both VEGFR1 and VEGFR2, whereas
those harvested from non-tumor bearing mice are only
VEGFR1+ [9,23]. When VEGFR2 is expressed, it
becomes the dominant receptor driving VEGF-induced
chemotaxis and specific blockade of the VEGF:VEGFR2
interaction is sufficient to inhibit chemotaxis [9,23]. The
most plausible explanation for the observed increase in
macrophage infiltration may be attributed to the
detected increase in VEGF expression and we have not
ruled out the possibility that GU81 may reduce macro-
phage infiltration, if given at a dose that could compen-
sate for the increased VEGF expression. We also cannot
rule out the idea that another unidentified cytokine may
be contributing to this increased macrophage infiltration
following GU81 therapy in this model.
Future studies to determine the maximum tolerated
dose (MTD) of GU81 in the MMTV-PyMT transgenic
breast cancer model are currently underway. Once this
has been established, mice will be treated at the MTD
for longer periods of time to optimize the efficacy of
GU81 both as a single agent and a combination therapy.
Furthermore, we are interested in the mechanism by
which GU81 increases VEGF expression and macro-
phage infiltration in vivo and are currently investigating
this phenomenon.
Conclusions
In conclusion, this study describes the use of a novel
VEGFR2 antagonist peptoid, GU81, to effectively control
tumor growth in combination with doxorubicin in a
transgenic model of breast cancer that closely mimics
human disease progression. This study further highlights
the use of peptoids as new and exciting biological tools
and potential therapeutics. Peptoids offer many desirable
biological characteristics. They are easy to handle and
inexpensive to synthesize and optimize. Furthermore,
peptoids have high serum-stability [13], are non-immu-
nogenic [34], and are cell permeable [35], thus making
them good candidates for use in drug discovery.
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